Starton Therapeutics news

Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide resulted in improvements in the mean time to total treatment failure (TTF) in the 216 mcg/day (58 days) and 288 mcg/day (58 days) gr

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced today the appointment of Moses Dodo to its Board of Directors.

“We are thrilled to welcome Moses to our Board; as an Independent Director Moses brings valuable reimbursement, banking and governance experience to our Board ” said Pedro Lichtinger, Chairman and CEO. “His exp

 Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today positive results from high-level data from its Phase 1 study of STAR-LLD, evaluating the pharmacokinetics (PK) and safety of the Company’s continuous delivery lenalidomide program. The Phase 1 study met all of its primary and secondary endpoints; in all subjects dosed with STAR-LLD, the plasma lenalidomide concentration (AUC) was 57% lower with STAR-LLD contin

Starton Therapeutics Inc., a clinical stage biotechnology company announced today that the Independent Data Monitoring Committee reviewed the totality of the safety data from the first two cohorts and recommended advancement to the third- and final dose escalation, where subjects will receive the highest infusion strength of STAR-LLD.  The ongoing Phase 1 STAR-LLD clinical trial is evaluating continuous delivery lenalidomide in healthy subjects. Eight subjects in the first two cohorts re

Starton Therapeutics Inc., a clinical stage biotechnology company provides updates on its first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide, in healthy subjects. Four subjects in the first cohort received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour washout period. The Independent Data Monitoring Committee reviewed the totality of the safety data from the first cohort and recommended a